Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH — BEST

HHT Clinical Trial

Official title:
Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.

Status Completed

Clinical Trial Summary

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hemorrhagic Hereditary Telangiectasia
HHT
Telangiectasis

Clinical Trial Details

NCT number	NCT06039124
Study type	Observational
Source	Hospices Civils de Lyon
Contact
Status	Completed
Phase
Start date	September 1, 2021
Completion date	August 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06266624` - Tourniquet-Test in HHT	N/A
Active, not recruiting	`NCT04150822` - Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
Recruiting	`NCT03850964` - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)	Phase 2/Phase 3
Completed	`NCT01314274` - Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 2
Completed	`NCT02389959` - Intranasal Bevacizumab for HHT-Related Epistaxis	Phase 4
Active, not recruiting	`NCT05550376` - Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia